Impurity Determination in Pharmaceutical Preparations: Testing Items, Analytical Methods, and Regula

Impurity determination in pharmaceutical preparations is a cornerstone of drug product quality control, ensuring that degradation products, residual solvents, elemental impurities, and mutagenic contaminants remain within safe and regulatorily acceptable limits throughout a product's shelf life. This technical article reviews the impurity categories defined by ICH Q3B, Q3C, Q3D, and M7, the dosage forms and test items commonly evaluated, and the HPLC, LC-MS, GC, and ICP-MS methodologies used by pharmaceutical manufacturers and accredited third-party laboratories for GMP release, stability, and registration testing.

Technical Overview

Impurities in pharmaceutical preparations are unwanted chemical entities present in the finished dosage form that are neither the active pharmaceutical ingredient (API) nor the intentional excipients. Unlike drug substance impurity profiles, which are dominated by synthesis-related impurities, the impurity landscape of a finished preparation is shaped primarily by degradation of the API, API–excipient interactions, migration from packaging components, and manufacturing process residues. Systematic determination of these impurities is therefore essential to establish product safety, support shelf-life assignment, and satisfy the analytical requirements of pharmacopoeial monographs and regulatory dossiers.

The internationally recognized framework for impurity control in drug products is built on the ICH quality guidelines: ICH Q3B(R2) for degradation products in new drug products, ICH Q3C for residual solvents, ICH Q3D(R1) for elemental impurities, and ICH M7 for assessment and control of DNA-reactive (mutagenic) impurities. These are complemented by ICH Q1A(R2) and Q1B for stress and photostability studies, and ICH Q2(R2) for validation of the analytical procedures themselves. Pharmacopoeial chapters such as USP <1086>, USP <232> and <233>, EP 2.4.20 and 5.10, and the corresponding general chapters of the Chinese Pharmacopoeia (ChP) operationalize these principles into monograph-level requirements.

• Organic impurities: degradation products of the API, adducts with excipients or oxygen, and carryover of process-related impurities from the drug substance
• Inorganic impurities: catalyst residues, heavy metals, reagents, and inorganic salts introduced during synthesis or manufacturing
• Residual solvents: volatile organic solvents remaining from synthesis, granulation, or coating operations
• Elemental impurities: catalyst- and environmental-derived elements with established permitted daily exposures (PDEs)
• Mutagenic and nitrosamine impurities: trace-level genotoxic contaminants controlled at parts-per-million or parts-per-billion concentrations
• Extractables and leachables: compounds migrating from container closure systems and manufacturing equipment into the product

A scientifically sound impurity control strategy is risk-based and lifecycle-oriented: it combines structural understanding of likely degradation pathways, stability-indicating analytical methods, justified acceptance limits, and ongoing verification through release testing and stability programs. Accredited third-party laboratories and GMP quality-control laboratories routinely perform these determinations under ISO/IEC 17025-aligned quality systems.

Testing Samples

Oral Solid Dosage Forms

Tablets, film-coated tablets, capsules, granules, and orally disintegrating forms represent the largest testing volume. Sample preparation typically involves extracting the API and its impurities from the powdered composite of multiple units, followed by centrifugation or filtration before chromatographic injection. Coating polymers, colorants, and high-potency low-dose products require special attention to extraction efficiency and matrix effects.

Sterile and Injectable Preparations

Solutions for injection, lyophilized powders for reconstitution, large-volume infusions, and pre-filled syringes carry elevated risk expectations because of their direct systemic administration. In addition to related substances, these preparations require rigorous control of extractables and leachables from elastomeric closures, glass delamination products, and nitrosamine or nitrite contamination, often with sub-ppb reporting limits.

Semi-Solid and Liquid Preparations

Creams, ointments, gels, oral solutions, syrups, suspensions, and emulsions present complex matrices in which the API may partition among aqueous, oily, and micellar phases. Method development must address complete recovery from the matrix, suppression of high levels of preservatives and antioxidants in the chromatogram, and degradation catalyzed by pH extremes or dissolved oxygen.

Specialty and Inhalation Dosage Forms

Metered-dose inhalers, dry-powder inhalers, nasal sprays, transdermal patches, and ophthalmic preparations combine stringent impurity limits with distinctive delivery-device interactions. Leachables from propellants, valve elastomers, adhesives, and polymer matrices are of particular concern and are evaluated under the safety-threshold logic of USP <1663> and <1664>.

Testing Items

Related Substances and Degradation Products

Related substances testing quantifies all individual and total impurities arising from API degradation and interaction products. Under ICH Q3B(R2), results are evaluated against reporting, identification, and qualification thresholds that scale with the maximum daily dose — for example, reporting thresholds of 0.1% for products dosed at up to 1 g per day and 0.05% above that dose, with identification thresholds of 0.2% and 0.1% respectively. Unknown impurities exceeding the identification threshold must be structurally elucidated, and those exceeding the qualification threshold require toxicological justification.

Residual Solvents

Volatile solvents are classified by ICH Q3C into three hazard classes: Class 1 solvents (benzene at 2 ppm, carbon tetrachloride at 4 ppm, 1,2-dichloroethane at 5 ppm, 1,1-dichloroethene at 8 ppm) are to be avoided; Class 2 solvents such as methanol (3000 ppm), acetonitrile (410 ppm), toluene (890 ppm), and dichloromethane (600 ppm) are restricted; Class 3 solvents are generally limited to 5000 ppm. Determination is typically performed on the finished preparation whenever the drug product manufacturing process itself uses solvents.

Elemental Impurities

ICH Q3D(R1) and USP <232> classify 24 elements by toxicity and likelihood of occurrence: Class 1 (arsenic, cadmium, mercury, lead) must be assessed for all routes of administration; Class 2A (cobalt, nickel, vanadium) and Class 2B (gold, palladium, platinum, iridium, osmium, rhodium, ruthenium, silver, selenium, thallium, lithium) depend on process inputs; Class 3 elements are relevant mainly for parenteral and inhaled products. Limits are expressed as permitted daily exposures, for example 5 µg/day for lead and cadmium, 15 µg/day for arsenic, and 30 µg/day for mercury by the oral route.

Nitrosamine and Mutagenic Impurities

Small-molecule nitrosamines such as NDMA, NDEA, NDBA, NPIP, and NMBA, as well as nitrosamine drug substance-related impurities (NDSRIs), are controlled at extremely low acceptable intakes — typically 18 to 96 ng/day depending on the compound — following global recalls and the 2020 refinement of ICH M7's cohort-of-concern provisions. A nitrosamine risk assessment evaluates amines, nitrites, and nitrosating conditions across the formulation, followed by confirmatory testing with LC-MS/MS or GC-MS/MS at ppb-level detection limits. ICH M7 additionally applies a threshold of toxicological concern of 1.5 µg/day to other potentially mutagenic impurities.

Extractables and Leachables

Extractables studies subject packaging components to exaggerated solvent and temperature conditions to catalogue potential migrants, while leachables studies monitor those compounds in the actual product throughout its shelf life. Results are interpreted against safety concern thresholds — for instance 0.15 µg/day for parenteral and orally inhaled products — and translated into analytical evaluation thresholds (AET) that define the sensitivity required of the screening methods.

Additional Determinations

• Chiral impurity and enantiomeric purity testing for stereoisomeric APIs
• Inorganic anion and cation residues by ion chromatography
• Preservative and antioxidant degradation products in multi-component liquid formulations
• Water content and oxidative degradation markers (peroxides, aldehydes) supporting mass-balance investigations

Testing Methods

HPLC and UHPLC with UV/PDA Detection

Reversed-phase HPLC remains the workhorse technique for related substances testing, using gradient elution with UV or photodiode-array detection referenced to validated wavelength maxima. Stability-indicating capability is demonstrated through forced degradation under acid, base, oxidative, thermal, humidity, and photolytic (ICH Q1B) conditions, with peak purity assessment by PDA spectral analysis to confirm the spectral homogeneity of the API peak. UHPLC systems with sub-2-micron columns provide higher resolution for complex impurity profiles and shorten analysis times significantly.

LC-MS/MS and High-Resolution Mass Spectrometry

Triple-quadrupole LC-MS/MS in multiple-reaction-monitoring mode delivers the sensitivity and selectivity needed for trace-level nitrosamines, genotoxic impurities, and nitrite screening, routinely achieving LOQs at or below 0.1 ppm and, for nitrosamines, in the low-ppb range. Quadrupole time-of-flight (Q-TOF) and Orbitrap high-resolution MS enable accurate-mass structural elucidation of unknown degradation products exceeding the ICH identification threshold, frequently supplemented by preparative isolation and NMR confirmation.

Gas Chromatography

Static headspace GC-FID under USP <467> / ICH Q3C conditions is the standard approach for residual Class 1, 2, and 3 solvents in preparations, with headspace GC-MS confirmation for identity. Dynamic headspace GC-MS/MS is applied to volatile nitrosamines such as NDMA in susceptible formulations, where liquid injection can generate artefactual formation of the analyte.

Elemental Analysis by ICP-MS and ICP-OES

Following closed-vessel microwave digestion, inductively coupled plasma mass spectrometry (ICP-MS) is the preferred technique for multi-element quantification at the ng/g sensitivity demanded by Class 1 and 2A element limits, using USP <233>-compliant Procedures 1 or 2 with internal standardization and interference management (collision/reaction cells). ICP-OES and graphite-furnace atomic absorption spectroscopy serve as alternatives for elements present at higher concentrations or when ICP-MS is unavailable. Method suitability must demonstrate detectability, specificity, accuracy, and precision per USP <233>.

Complementary and Orthogonal Techniques

Ion chromatography with suppressed conductivity quantifies inorganic anions and cations; capillary electrophoresis and HPTLC offer orthogonal selectivity for polar or ionic impurities; supercritical fluid chromatography resolves non-chiral and chiral impurities that co-elute in reversed-phase systems; and quantitative NMR provides absolute quantification during impurity reference standard assignment.

Method Validation and Data Integrity

All quantitative impurity methods must be validated in accordance with ICH Q2(R2), covering specificity, linearity across the reporting range, accuracy by recovery at the reporting threshold, repeatability and intermediate precision, detection and quantitation limits, range, robustness, and sample and standard solution stability. Analytical procedures should be developed within a structured framework consistent with ICH Q14, and all chromatographic data handling must comply with the data-integrity expectations of ALCOA+ principles and current GMP annexes.

Applications

Impurity determination in finished preparations supports decision points across the entire pharmaceutical product lifecycle, from early development through commercial supply and post-approval change management. Typical engagements entrusted to accredited third-party laboratories and in-house GMP laboratories include:

• Batch release testing of related substances, residual solvents, and elemental impurities against registered specifications
• ICH Q1A(R2) long-term, intermediate, and accelerated stability programs, including shelf-life justification and trend evaluation of growing degradation products
• Method development, validation, and transfer for new drug applications, abbreviated applications for generics, and post-approval changes
• Nitrosamine risk assessment and confirmatory testing triggered by regulatory requests or formulation changes
• Extractables and leachables studies for container closure systems, single-use bioprocessing contact materials, and drug-device combination products
• Out-of-specification and out-of-trend investigations, mass-balance reconciliation, and structural elucidation of unknown impurities
• Comparative impurity profiling for generic versus reference-listed products and for biosimilar analytical similarity exercises
• Cleaning verification support and hold-time studies for manufacturing equipment and process intermediates

FAQ

What is the difference between impurities in a drug substance and impurities in a pharmaceutical preparation?

Drug substance impurity profiles are governed by ICH Q3A and are dominated by starting materials, reagents, by-products, and intermediates from the synthesis route. Impurities in the finished preparation, governed by ICH Q3B, arise mainly from degradation of the API during formulation, storage, and use, from API–excipient or API–container interactions, and from solvents or elements introduced by the drug product manufacturing process itself. Both profiles must be controlled, but the analytical focus and the degradation-mechanism understanding differ substantially.

How are acceptance limits for degradation products established?

Limits are set at or below the ICH Q3B qualification threshold, or above it only when supported by toxicological data, literature precedents, or substantial human exposure history. For known degradation products with qualified toxicity data, the permissible level is derived from the acceptable daily intake; for generics, limits are typically set to match or be more stringent than those of the reference product, taking daily dose into account.

Why has nitrosamine testing become a routine expectation?

Global regulatory findings of NDMA, NDEA, and related nitrosamines in sartan, ranitidine, metformin, and other products demonstrated that secondary, tertiary, and quaternary amines combined with nitrites or nitrosating conditions can form nitrosamines at ppb levels — including nitrosamine drug substance-related impurities unique to each API. Regulators worldwide consequently require documented risk assessments and, where risk cannot be excluded, sensitive confirmatory testing using LC-MS/MS or GC-MS/MS methods validated at the applicable acceptable intake.

What sensitivity is required for elemental impurity testing?

The required sensitivity depends on the daily dose and the permitted daily exposure of each element. In practice, ICP-MS methods are validated to quantify Class 1 elements such as lead, cadmium, arsenic, and mercury down to concentrations well below the 30% control threshold of their J-values or PDE-derived limits, ensuring the analytical procedure meets the detectability criteria of USP <233> even for high-dose or low-PDE scenarios.

Can a single chromatographic method cover all impurities in a preparation?

No single method can universally resolve organic degradation products, residual solvents, elemental impurities, and trace genotoxic contaminants because these classes differ fundamentally in volatility, polarity, and concentration range. A rational control strategy combines an orthogonal set of techniques — typically HPLC/UHPLC for related substances, headspace GC for solvents, ICP-MS for elements, and LC-MS/MS for trace mutagens — each individually validated for its intended purpose.

How long does impurity method development and validation typically take?

Development of a stability-indicating related-substances method, including forced degradation, specificity demonstration, and full ICH Q2(R2) validation, typically requires six to twelve weeks depending on matrix complexity and the number of known impurity reference standards available. Trace-level nitrosamine or mutagenic impurity methods may require additional time for trace standard handling, matrix-matched validation, and sensitivity confirmation at the required ppb limits.